New data shows that long-lasting treatment reduces bleeding episodes in hemophilia
New evidence from real-life clinical practice in the UK, presented today at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, shows that people with hemophilia A treated with an extended half-life (EHL) clotting factor have fewer bleeds than with previously available treatments.
The new findings, based on an analysis of the UK National Hemophilia Database, indicate that treatment with efmoroctocog alfa factor VIII (rFVIIIFc), led to a reduction in bleeding episodes in patients living with hemophilia A.
The hemophilia drug is marketed under the trade name Elocta by Swedish Orphan Biovitrum (STO: SOBI) and partnered with US biotech Biogen (Nasdaq: BIIB). SOBI reported first-quarter 2018 sales of 649 million kronor ($75 million), up 159% on the first quarter of 2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze